Focus:
News
-
3 April 2020
Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs
Vir Biotechnology and Alnylam Pharmaceuticals have expanded their multi-target infectious diseases alliance to include up to three targets for SARS-CoV-2, the novel coronavirus that causes Covid-19.
-
3 April 2020
FluGen, Bharat Biotech and UW–Madison partner on Covid-19 vaccine
Vaccine development companies FluGen and Bharat Biotech have partnered with the University of Wisconsin–Madison to develop and evaluate a Covid-19 vaccine candidate, called CoroFlu.
-
3 April 2020
Kite licences Teneobio’s multiple myeloma targeting antibodies
Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to some antibodies intended for the treatment of multiple myeloma.
-
3 April 2020
Novartis and Incyte to trial Jakavi for Covid-19
Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
-
3 April 2020
Covid-19 vaccine candidate yields promising data in mice
Researchers at University of Pittsburgh School of Medicine in the US have reported encouraging results from initial tests of a Covid-19 vaccine candidate, PittCoVacc, delivered using a fingertip-sized patch in...
-
3 April 2020
Amgen and Adaptive Biotechnologies to develop Covid-19 drug
Amgen has partnered with Adaptive Biotechnologies to develop a drug candidate that could prevent and treat Covid-19 coronavirus infection.
-
3 April 2020
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial
Apeiron Biologics has secured approvals from regulatory agencies in Austria, Germany and Denmark to conduct a Phase II clinical trial of APN01 for the treatment of Covid-19.
-
3 April 2020
Global confirmed Covid-19 cases exceed one million
The Covid-19 cases have crossed one million globally, with the pandemic being responsible for more than 52,000 deaths so far.
-
2 April 2020
Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS
Citius Pharmaceuticals has entered an exclusive six-month option agreement to licence a stem cell therapy from Novellus to treat acute respiratory distress syndrome (ARDS) related to Covid-19 infection.
-
2 April 2020
Gilead initiates two studies of remdesivir for Covid-19 in UK
Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.